Investing in Tomorrow's Health

NCL Investment Management invests transformational equity capital in entrepreneurs who have truly innovative technologies.

Our Investment Philosophy

The Modernisation of Healthcare will be one of the Greatest Growth Drivers of the 21st Century

NCL is a specialist healthcare investor.  We create value by identifying companies who are at the forefront of transformational change.  By applying the capital and human skills required to navigate this rapidly evolving sector, we prepare our companies to succeed both clinically and commercially.

Our focus is on the pioneers. Companies that are actively using innovation and technological advancement to help prevent, treat and cure a wide range of conditions.

Our mission is to address the challenges of our future health needs, whilst creating the next generation of valuable businesses.

 

 

Our Portfolio

Our investments keep making strides in their fields and winning awards in recognition.

Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo

NCLs Health Technology Fund II

NCL is currently investing from its Health Technology Fund II.  The fund has been designed to take positions in pioneering new technologies that can create significant patient impact and produce upper quartile investment returns.

The fund has launched in partnership with several leading UK institutions including Kings College, NHS and our delivery partner Catalent Inc (NYSE: CLT). Documentation can be provided to professional investors only upon request.

Whether a potential investor or an entrepreneur we invite you to discuss your goals and ambitions with us.

Our Team

Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management. Our investment process is supported by expert scientific advisors

Jerry Biggs's headshot

Jerry Biggs

Managing Partner
View Profile
Jonathan Synett's headshot

Jonathan Synett

CIO / Managing Partner
View Profile
Pat O’Neill's headshot

Pat O’Neill

Managing Partner
View Profile
Francis W. Chen PHD's headshot

Francis W. Chen PHD

Scientific Advisor
View Profile
Emma Sugrue's headshot

Emma Sugrue

Executive Assistant
View Profile

Our News

LifeArc and UK government’s Future Fund provide £3.0m in funding to Centauri Subsidiary Avvinity Therapeutics

LifeArc, an independent medical research charity,announces a £3.0m co-investment in British biotech Avvinity Therapeutics alongside the UK government’s Future Fund. Lead investor LifeArc leveraged … Continued

Read more

Immune Regulation Limited raises £40.6 million / $53.4 million Series B Equity Financing

Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies (London UK and Boston USA, 21 … Continued

Read more

Immune system ‘bully boys’ square up to coronavirus crisis

Scalable, affordable, effective. Read about TC Biopharm’s stunning progress in the Financial Times here. “After winning approval from the UK’s Medicines and Healthcare Products … Continued

Read more

Want to discuss an investment opportunity with us?

Submit an Opportunity